Guide
How PDE5 inhibitors are understood to act in erectile physiology
An educational overview of the PDE5 inhibitor class and the nitric oxide and cGMP signaling pathway it is understood to act on.
On this page
What PDE5 inhibitors are
Phosphodiesterase type 5 (PDE5) inhibitors are a class of small-molecule compounds. Tadalafil and sildenafil are two commonly discussed members of this class. Each is generally described as a molecule designed to bind to and slow the activity of a specific enzyme, phosphodiesterase type 5, which is found in the smooth muscle of blood vessel walls and in other tissues throughout the body.
Because the members of this class share a common target, they are often grouped together and discussed by their shared mechanism rather than by any single product name. The individual molecules differ from one another in their chemical structure and in how long they are understood to remain active in the body, but they are all designed to interact with the same enzyme.
This guide is educational and describes how the class is understood to act at the level of cell signaling. It is not medical advice, and it does not describe what any individual should expect. Whether a product in this class is appropriate for a given person is a clinical decision that belongs to an independent licensed provider, not to the patient or to this material.
The nitric oxide and cGMP signaling pathway
The pathway that PDE5 inhibitors are understood to act on begins with a signaling molecule called nitric oxide. During sexual stimulation, nerve endings and the cells lining nearby blood vessels are understood to release nitric oxide into the surrounding tissue. This step is generally described as depending on stimulation being present rather than occurring on its own.
Once released, nitric oxide is understood to diffuse into nearby smooth muscle cells, where it activates an enzyme called guanylate cyclase. Guanylate cyclase is generally described as converting a molecule called GTP into cyclic guanosine monophosphate, abbreviated cGMP. cGMP then acts as what is often called a second messenger, meaning it is understood to carry a signal onward inside the cell.
In simple terms, this sequence is understood to translate an external cue, such as stimulation, into an internal chemical signal. cGMP is the molecule that carries that signal in this particular pathway, and its rise and fall within the cell is understood to shape how the surrounding smooth muscle behaves.
PDE5, cGMP breakdown, and smooth-muscle tone
Inside the cell, cGMP does not remain indefinitely. The PDE5 enzyme is generally described as the main pathway by which cGMP is broken down and cleared. In this way, PDE5 acts as a kind of off-switch for the signal that cGMP carries, and the balance between how much cGMP is made and how quickly PDE5 removes it is understood to determine how long the signal persists.
PDE5 inhibitors are understood to bind to this enzyme and slow the rate at which it breaks down cGMP. By slowing that breakdown, the class is understood to allow cGMP to persist longer within the smooth muscle cell than it otherwise would. This is the central mechanism by which the class is generally described, and it is framed as an effect on a signaling molecule rather than as any promised result.
cGMP itself is understood to promote relaxation of the smooth muscle within blood vessel walls. When this smooth muscle relaxes, the vessels are understood to widen, a process generally described as vasodilation, which is associated with increased local blood flow. The connection between the enzyme, the second messenger, and smooth-muscle tone is the framework through which this drug class is described in physiology and pharmacology.
Daily and as-needed formulations
Within the PDE5 inhibitor class, products are generally described as being organized around two broad approaches. Some are discussed in the context of use on an as-needed basis, taken in relation to anticipated activity, while others are discussed in the context of a regular daily regimen. These are descriptions of how formulations are structured, not recommendations, and they say nothing about what any individual should do.
The molecules also differ in how long each is understood to remain active in the body after it is taken. Tadalafil is generally described as remaining active for a longer window than sildenafil, which is generally described as having a shorter active window. These are neutral descriptions of pharmacokinetics, not claims that one molecule is preferable to another; suitability depends entirely on the individual and the prescribing provider's judgment.
This guide does not provide dosing information of any kind, including amounts, timing, or frequency. Any decision about which formulation, which molecule, and what dose may be appropriate is made by the independent licensed provider who reviews a request, taking into account the individual's health history and current medications. The patient requests; the provider decides.
How prescription review works on OpenDoseRx
On OpenDoseRx, the process begins when you choose a product and strength and then complete a medical intake. The intake asks about your health history, current medications, and other relevant information. Submitting a request is not a prescription and is not a guarantee that anything will be dispensed; it is a request for an independent clinical review.
An independent licensed U.S. provider reviews each submitted intake and makes the clinical decision. If the provider approves an order, it is filled by a licensed U.S. pharmacy. If the provider declines the request, the order is refunded in full. The decision to prescribe, and any decision about the product, formulation, or dose, rests with that independent provider.
Products discussed here may include compounded medications, which are not FDA-approved drugs, and statements in this guide have not been evaluated by the FDA. This material is educational only and is not medical advice. It does not replace the relationship with your own healthcare provider, and you should share your full medical history and any concerns with a licensed clinician who knows your care.
Common questions
- Do PDE5 inhibitors produce an effect on their own?
- The class is generally described as acting within the nitric oxide and cGMP pathway, which is understood to begin with nitric oxide release that follows sexual stimulation. For that reason, the mechanism is described as depending on stimulation being present rather than acting independently of it. This is an educational description of the pathway, not a statement about what any individual should expect.
- What is the difference between daily and as-needed forms?
- Within the class, some formulations are discussed in the context of use on an as-needed basis and others in the context of a regular daily regimen, and the individual molecules differ in how long each is understood to remain active in the body. These are neutral descriptions of how formulations are structured. Which approach, molecule, and dose may be appropriate is determined by the independent licensed provider who reviews your request.
- Are these products FDA-approved?
- Products offered in this category may include compounded medications, which are not FDA-approved drugs, and statements in this guide have not been evaluated by the FDA. This material is educational only and is not medical advice. Any questions about a specific product's regulatory status or its suitability for you should be directed to a licensed provider.
Ready when you are
Sildenafilfrom $22.00
- Your exact strength
- Licensed provider review
- Full refund if declined
Also relevant
Exact strengths and prices up front — a licensed provider reviews every request.
Browse sexual health & intimacy
Exact strengths and prices up front — reviewed by a licensed U.S. provider.
This guide is for general education and is not medical advice. Compounded medications are not FDA-approved drugs, and statements on this site have not been evaluated by the FDA. A licensed provider reviews every prescription request.
